Table II.
Cohort 2 patient characteristics.
| Characteristics | gBRCAm (n=18) | BRCAwt (n=55) | All (n=73) |
|---|---|---|---|
| Age, median (range), years | 57.5 (36–78) | 65 (30–84) | 64 (30–84) |
| Tumor status | |||
| Primary stage III/IV | 1 (6%) | 8 (15%) | 9 (12%) |
| Recurrent | 17 (94%) | 47 (85%) | 64 (88%) |
| Histology | |||
| HGSOC | 18 (100%) | 52 (95%) | 70 (96%) |
| Clear cell | 0 | 3 (5%) | 3 (4%) |
| Years from initial diagnosis | |||
| <5 years | 13 (72%) | 42 (76%) | 55 (75%) |
| ≥5 years | 5 (28%) | 13 (24%) | 18 (25%) |
| Number of previous lines of therapy, median (range) | 3 (1–11) | 5 (1–14) | 4 (1–14) |
| Platinum sensitivity | |||
| On active treatment with first line carboplatin/taxol vs. | 0 (0%) | 8 (15%) | 8 (10%) |
| Platinum-sensitive recurrent disease vs. | 9 (50%) | 7 (13%) | 16 (22%) |
| Platinum-resistant recurrent disease | 9 (50%) | 40 (72%) | 49 (68%) |
| Prior bevacizumab | |||
| Yes | 7 (64%) | 28 (51%) | 35 (48%) |
| No | 11 (36%) | 27 (49%) | 38 (52%) |
| Prior CTLA-4 inhibitor, prior vaccine and/or PD-1/PDL-1 blockade | 1 (5.6%) | 2 (3.6%) | 3 (4.1%) |
gBRCAm, germline BRCA mutation; BRCAwt: germline BRCA wild-type; HGSOC, high grade serous ovarian carcinoma; CTLA-4, cytotoxic T lymphocyte-associated protein 4; PD-1, programmed cell death protein 1; PDL-1, programmed death ligand-1.